Chinese Biopharma Adopts Medidata Cloud in Pediatric Vaccine Program

Published on: September 9, 2015

Applied Clinical Trials

Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that its Clinical Cloud platform has been adopted by Walvax Biotechnology.

Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that its Clinical Cloud platform has been adopted by Walvax Biotechnology, a biopharmaceutical company in China. Walvax is using the technology to improve data management collection and management in the first multi-center trials of its novel research on a vaccine for pneumococcal conjugate (PCV13).

Read the full release here.